Mereo Licenses Navicixizumab to Oncologie for Worldwide Development, Commercialization

Mereo Licenses Navicixizumab to Oncologie for Worldwide Development, Commercialization
0
(0)

Mereo BioPharma has licensed its experimental therapy navicixizumab (OMP-305B83) — designed to treat advanced, heavily pretreated ovarian cancer — to Oncologie for worldwide development and commercialization.

Under the terms of the agreement, Mereo will get an upfront payment of $4 million. That will be followed by a $2 million outlay contingent upon a milestone known as CMC, or chemistry, manufacturing and controls — the ability to produce, analyze, and store a product.

Mereo also stands to get $300 million in future clinical, regulatory and commercial milestones, plus royalties on global annual net sales and a negotiated percentage of certain sublicensing revenues.

Oncologie will be responsible for all future research, development, and commercialization of navicixizumab.

“We believe Oncologie is expertly positioned to further advance navicixizumab through clinical development and towards potential commercialization,” Denise Scots-Knight, PhD, CEO of Mereo, said in a press release.

The U.S. Food and Drug Administration (FDA) granted fast track designation to navicixizumab in October as a potential therapy for heavily pretreated ovarian cancer.

The treatment is designed for patients who have received more than two prior therapies and/or prior bevacizumab — a therapeutic antibody against the vascular endothelial growth factor (VEGF) protein, which is necessary for the formation of new blood vessels.

Navicixizumab is a bispecific antibody that targets both VEGF and its ligand, Delta-like ligand 4 (DLL4). DLL4 is involved in the development of cancer stem cells and the formation of new blood vessels essential to tumor growth.

The fast track designation was based on positive results from a Phase 1a study (NCT02298387) and an ongoing Phase 1b study (NCT03030287) evaluating navicixizumab in people with advanced heavily pretreated ovarian cancer.

The Phase 1a study included 66 patients with refractory solid tumors who received escalating doses of navicixizumab once every three weeks. Among the 12 ovarian cancer patients included in the study, three (25%) attained a partial response of a decrease of at least 30% in tumor size, while four (33%) had stable disease.

The Phase 1b trial is now assessing a combination of navicixizumab plus the chemotherapy agent Taxol (paclitaxel) in people with platinum-resistant ovarian, fallopian, or primary peritoneal cancer who received three or more prior therapies and/or bevacizumab.

At the time of the last analysis, the trial had included 44 of the 60 estimated participants, 41% of whom responded to treatment. They also lived a median of 7.3 months without signs of disease worsening.

The FDA has agreed in principle on an outline for a Phase 2 clinical trial that could potentially support accelerated approval of navicixizumab in a heavily pretreated, platinum-resistant ovarian cancer population.

“We believe navicixizumab is a strong strategic fit with out portfolio of innovative oncology assets, and we are excited to enter into this agreement with Mereo,” said Laura E. Benjamin, PhD, CEO of Oncologie.

“We seek to leverage the strong development and regulatory progress Mereo has already made to continue its development and ultimately make this investigational therapy available to patients as quickly as possible,” Benjamin said.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 129
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • Newk's Cares fundraising
  • pap smears and cancer diagnosis

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?